Figure 2 illustrates the correlation between KRAS mutations and patient survival rates across select cancer types, based on publicly available datasets from cBioPortal [94,95], emphasizing the clinical impact of specific mutation hotspots such as glycine 12 (G12) and alanine 59 (A59). This evidence concerns the gene KRAS and cancer.